NERLYNX dose modification is recommended based on individual safety and tolerability. Management of some adverse reactions may require dose interruption and/or dose reduction of treatment with NERLYNX as shown in Tables 2 to 5 below. Discontinue NERLYNX in patients who fail to recover to Grade 0-1 from treatment-related toxicity, for toxicities that result in a treatment delay of > 3 weeks, or for patients who are unable to tolerate 120 mg NERLYNX daily. Additional clinical situations may result in dose adjustments as clinically indicated (e.g., intolerable toxicities, persistent Grade 2 adverse reactions, etc.).